The paradigm for managing primary immune thrombocytopenia (ITP) in adults has changed
with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options for …

Approximately 80% of adult patients with immune thrombocytopenia (ITP) have treatment
failure with corticosteroids or become dependent on them and require second-line therapy …

Splenectomy is an effective therapy for steroid-refractory or dependent immune
thrombocytopenia (ITP). With the advent of medical alternatives such as rituximab and …

Although splenectomy is still considered the most effective curative treatment for immune
thrombocytopenia (ITP), its use has significantly declined in the last decade, especially since …

The management of patients with immune thrombocytopenia (ITP) is rapidly evolving. Over
the last 15 years, a number of novel treatments have improved practice, with many steroid …

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by both reduced
platelet survival and suppression of megakaryocyte and platelet development. It can either …

Background Immune thrombocytopenia is characterised by immune-mediated destruction
and suboptimum production of platelets. Despite the absence of supporting evidence …

Introduction Primary immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by a low platelet count (< 100× 109/L) with an increased risk of bleeding …

Immune thrombocytopenia (ITP) is a common hematologic disorder. Its pathogenesis
involves both accelerated platelet destruction and impaired platelet production. First-line …

Immune thrombocytopenia (ITP) comprises a syndrome of diverse disorders that have in
common immune‐mediated thrombocytopenia, but that differ with respect to pathogenesis …